Novartis International has decided to let go of its eye care business, Alcon, keeping only its portfolio of pharmaceutical products. In January, the group had announced a strategic review of the division, which is now completed. After examining alternative options including a public offering for Alcon, the management determined that ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.